Zura Bio Limited
- ZURA
- NASDAQ
- Biotechnology
- Clinical-Stage Biotech
- Immune/Inflammatory Diseases
- Anti-IL7Rα Therapy
$3.81
Today −1.80%Quote Oct 19, 2026, 08:00 PM UTC
−14.57%over the last month
Max drawdown −15.5%From 1-month high −15.5%3 months −32.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Zura Bio
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
40
Market value
$365.1M
Quote Oct 19
Analyst target
$20.00
+424.9% from here
Floor
$3.56
6.6% below price
Resistance
$3.90
2.4% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ZURAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free